Efficacy of antiviral therapy for chronic hepatitis B with nonalcoholic fatty liver disease

Ling QING; Weiqiang HUANG; Xiaohe LI; Feng CHEN; Yingxia LIU

doi:10.3969/j.issn.1001-5256.2021.09.015

Volume 37 Issue 9

Sep. 2021

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2021 > 37(9): 2075-2080

PDF( 2025 KB)

Efficacy of antiviral therapy for chronic hepatitis B with nonalcoholic fatty liver disease

DOI: 10.3969/j.issn.1001-5256.2021.09.015

Ling QING¹,
Weiqiang HUANG^{2, 3},
Xiaohe LI²,
Feng CHEN^{2, 4
,
,},
Yingxia LIU^{2
,
,}

1.
Clinical Medicine, University of South China, Hengyang, Hunan 421000, China
2.
Department of Infectious Diseases, Shenzhen Third People's Hospital, Shenzhen, Guangdong 518112, China
3.
Department of Ultrasound, Pingxiang Second People's Hospital, Pingxiang, Jiangxi 337000, China
4.
Digestive Medicine Center, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, Guangdong 518107, China

Research funding:

National Natural Science Foundation of China (81873573);

National Natural Science Foundation of China (81800525)

Received Date: 2021-07-30
Accepted Date: 2021-08-31
Published Date: 2021-09-20

Abstract

Abstract

Objective To investigate the influence of nonalcoholic fatty liver disease (NAFLD) on the antiviral response of patients with chronic hepatitis B (CHB), and to provide a reference for clinical treatment of such patients. Methods A total of 187 patients who attended Shenzhen Third People's Hospital from January 2011 to December 2017 were enrolled and divided into CHB group with 43 patients, NAFLD group with 41 patients, and CHB+NAFLD group with 103 patients. Related indices were measured at enrollment different time points of follow-up, including body height, body weight, alanine aminotransferase (ALT), aspartate aminotransferase, four blood lipid parameters, four indicators of liver fibrosis, aspartate aminotransferase-to-platelet ratio index, HBsAg, HBeAg, anti-HBe, and HBV DNA quantification, and the CHB patients and the CHB+NAFLD patients receiving antiviral therapy were compared in terms of treatment outcome at weeks 12, 24, 48, 72, and 96 of antiviral therapy. The Kruskal-Wallis H test was used for comparison of non-normally distributed continuous data between multiple groups, and the Wilcoxon rank-sum test was used for comparison between two groups; the chi-square test was used for comparison of categorical data between groups. Results Compared with the NAFLD group at baseline, the CHB group and the CHB+NAFLD group had significantly lower platelet count, ALT, gamma-glutamyl transpeptidase (GGT), alkaline phosphatase, and right lobe of liver oblique diameter (all P < 0.05), and compared with the CHB group, the CHB+NAFLD group had significantly higher body mass index, total cholesterol, and triglyceride and a significantly lower spleen thickness (all P < 0.05), while there were no significant differences in the other indicators between the two groups at baseline (all P > 0.05). At week 12 of antiviral therapy, there were no significant differences in liver fibrosis markers and inflammatory indices between the CHB group and the CHB+NAFLD group (all P > 0.05); compared with the CHB+NAFLD group at weeks 24 and 48, the CHB group had significantly greater reductions in ALT (Z=-2.128 and -3.055, both P < 0.05) and GGT (Z=-2.025 and -1.631, both P < 0.05); at week 48, the CHB group and the CHB+NAFLD group had a significant reduction in HBV DNA (Z=-6.445 and -4.415, both P < 0.001), and the CHB group had a significantly greater reduction. The CHB+NAFLD group had a significantly lower HBV DNA clearance rate than the CHB group at different time points of antiviral therapy (χ²=14.237, 13.961, 15.226, 10.462, and 13.030, all P < 0.05). At week 48 of antiviral therapy, the CHB+NAFLD group had a significantly lower HBeAg clearance rate than the CHB group (χ²=5.309, P=0.021), while there was no significant difference between the two groups at week 96 (χ²=0.117, P=0.732). At weeks 24, 48, 72, and 96 of antiviral therapy, the CHB+NAFLD group had a significantly lower ALT normalization rate than the CHB group (χ²=12.049, 5.287, 11.407, and 11.375, all P < 0.05). Conclusion NAFLD reduces the antiviral response of CHB patients and prolongs the duration of antiviral therapy.
- Hepatitis B, Chronic,
- Non-alcoholic Fatty Liver Disease,
- Antiviral Agents,
- Treatment Outcome

FullText(HTML)

References(18)

References

[1]	Chinese Society of Hepatology and Chinese Society of Infectious Disease, Chinese Medical Association. The guideline of prevention and treatment for chronic hepatitis B: A 2015 update[J]. J Clin Hepatol, 2015, 31(12): 1941-1960. DOI: 10.3969/j.issn.1001-5256.2015.12.002. 中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南(2015年更新版)[J]. 临床肝胆病杂志, 2015, 31(12): 1941-1960. DOI: 10.3969/j.issn.1001-5256.2015.12.002.
[2]	YOUNOSSI Z, ANSTEE QM, MARIETTI M, et al. Global burden of NAFLD and NASH: Trends, predictions, risk factors and prevention[J]. Nat Rev Gastroenterol Hepatol, 2018, 15(1): 11-20. DOI: 10.1038/nrgastro.2017.109.
[3]	WONG SW, CHAN WK. Epidemiology of non-alcoholic fatty liver disease in Asia[J]. Indian J Gastroenterol, 2020, 39(1): 1-8. DOI: 10.1007/s12664-020-01018-x.
[4]	LI J, ZOU B, YEO YH, et al. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019: A systematic review and meta-analysis[J]. Lancet Gastroenterol Hepatol, 2019, 4(5): 389-398. DOI: 10.1016/S2468-1253(19)30039-1.
[5]	LIU Q, YANG Y, MAO J, et al. Analysis of prevalence status and influencing factors of fatty liver in crowd in Wuhan city[J]. Chin Nurs Res, 2016, 30(31): 3927-3929. DOI: 10.3969/j.issn.1009-6493.2016.31.025. 刘倩, 杨莹, 毛靖, 等. 武汉市人群脂肪肝患病情况及其影响因素分析[J]. 护理研究, 2016, 30(31): 3927-3929. DOI: 10.3969/j.issn.1009-6493.2016.31.025.
[6]	ZHANG J, LIN S, JIANG D, et al. Chronic hepatitis B and non-alcoholic fatty liver disease: Conspirators or competitors?[J]. Liver Int, 2020, 40(3): 496-508. DOI: 10.1111/liv.14369.
[7]	SETO WK, YUEN MF. Nonalcoholic fatty liver disease in Asia: emerging perspectives[J]. J Gastroenterol, 2017, 52(2): 164-174. DOI: 10.1007/s00535-016-1264-3.
[8]	Group of Fatty Liver and Alcoholic Liver Diseases, Society of Hepatology, Chinese Medical Association. Guidelines for Management of non-alcoholic fatty liver disease[J]. J Clin Hepatol, 2010, 26(2): 120-124. http://lcgdbzz.org/cn/article/doi/1001-5256%20(2010)%2002-0120-05 中华医学会肝脏病学分会脂肪肝和酒精性肝病学组. 非酒精性脂肪性肝病诊疗指南[J]. 临床肝胆病杂志, 2010, 26(2): 120-124. http://lcgdbzz.org/cn/article/doi/1001-5256%20(2010)%2002-0120-05
[9]	CHOI H, BROUWER WP, ZANJIR W, et al. Nonalcoholic steatohepatitis is associated with liver-related outcomes and all-cause mortality in chronic hepatitis B[J]. Hepatology, 2020, 71(2): 539-548. DOI: 10.1002/hep.30857.
[10]	SCHUPPAN D, SURABATTULA R, WANG XY. Determinants of fibrosis progression and regression in NASH[J]. J Hepatol, 2018, 68(2): 238-250. DOI: 10.1016/j.jhep.2017.11.012.
[11]	KOYAMA Y, BRENNER DA. Liver inflammation and fibrosis[J]. J Clin Invest, 2017, 127(1): 55-64. DOI: 10.1172/JCI88881.
[12]	MORALES MR, SENDRA C, ROMERO-GOMEZ M. Hepatitis B and NAFLD: Lives crossed[J]. Ann Hepatol, 2017, 16(2): 185-187. DOI: 10.5604/16652681.1231556.
[13]	XIAO CH, LI XH, ZHANG CL, et al. Efficacy of adefovir dipivoxil in treatment of chronic hepatitis B patients with non-alcoholic fatty liver disease[J]. J Clin Hepatol, 2015, 31(2): 266-268. DOI: 10.3969/j.issn.1001-5256.2015.02.029. 肖春花, 利旭辉, 张春兰, 等. 阿德福韦酯治疗慢性乙型肝炎合并非酒精性脂肪性肝病的疗效观察[J]. 临床肝胆病杂志, 2015, 31(2): 266-268. DOI: 10.3969/j.issn.1001-5256.2015.02.029.
[14]	JIN X, CHEN YP, YANG YD, et al. Association between hepatic steatosis and entecavir treatment failure in Chinese patients with chronic hepatitis B[J]. PLoS One, 2012, 7(3): e34198. DOI: 10.1371/journal.pone.0034198.
[15]	CHEN MQ, WU JM, CHEN J, et al. The effect of non-alcoholic fatty liver disease on virologic response in patients with hepatitis B e antigen-positive chronic hepatitis B treated with nucleoside analogues[J]. Clin J Infect Dis, 2014, 32(3): 158-161. DOI: 10.3760/cma.j.issn.1000-6680.2014.03.007. 陈梅琴, 吴金明, 陈娟, 等. 合并非酒精性脂肪性肝病对e抗原阳性慢性乙型肝炎患者核苷类似物抗病毒疗效的影响[J]. 中华传染病杂志, 2014, 32(3): 158-161. DOI: 10.3760/cma.j.issn.1000-6680.2014.03.007.
[16]	WU L, PAREKH VV, GABRIEL CL, et al. Activation of invariant natural killer T cells by lipid excess promotes tissue inflammation, insulin resistance, and hepatic steatosis in obese mice[J]. Proc Natl Acad Sci U S A, 2012, 109(19): e1143-e1152. DOI: 10.1073/pnas.1200498109.
[17]	LU HH, CHEN QQ, SUN FF, et al. Progress on chronic hepatitis B complicated with non-alcoholic fatty liver disease[J/CD]. Chin J Liver Dis (Electronic Edition), 2020, 12(3): 12-16. DOI: 10.3969/j.issn.1674-7380.2020.03.003. 陆慧慧, 陈琦琪, 孙芳芳, 等. 慢性乙型肝炎合并非酒精性脂肪性肝病研究进展[J/CD]. 中国肝脏病杂志(电子版), 2020, 12(3): 12-16. DOI: 10.3969/j.issn.1674-7380.2020.03.003.
[18]	ZHANG RN, PAN Q, ZHANG Z, et al. Saturated fatty acid inhibits viral replication in chronic hepatitis B virus infection with nonalcoholic Fatty liver disease by toll-like receptor 4-mediated innate immune response[J]. Hepat Mon, 2015, 15(5): e27909. DOI: 10.5812/hepatmon.15(5)2015.27909.

Relative Articles

[1]	Yuqing YANG, Jia SHANG, Chengzhen LU, Song YANG, Hongyu CHEN, Jiali PAN, Yifan HAN, Hongli XI, Qian KANG, Ning TAN, Xiaoyuan XU. Influencing factors for direct-acting antiviral therapy failure in treatment of hepatitis C[J]. Journal of Clinical Hepatology, 2022, 38(5): 1059-1063. doi: 10.3969/j.issn.1001-5256.2022.05.016
[2]	Tao WANG, Fenghui LI, Jing LIANG, Huiling XIANG, Fang LIU, Hongmin LYU, Baoxin QIAN, Jiajun TIAN. Clinical effect of direct-acting antiviral agents in treatment of chronic hepatitis C patients with thrombocytopenia[J]. Journal of Clinical Hepatology, 2022, 38(1): 91-96. doi: 10.3969/j.issn.1001-5256.2022.01.014
[3]	Hao WANG, Shan SHAN, Hong YOU, Xiaoyuan XU, Lai WEI, Jinlin HOU, Hui ZHUANG, Yuanyuan KONG, Jidong JIA, China Registry of Hepatitis B (CR-HepB) Group. Effect of the change in antiviral therapy indication in increasing the treatment rate of chronic hepatitis B[J]. Journal of Clinical Hepatology, 2022, 38(6): 1269-1274. doi: 10.3969/j.issn.1001-5256.2022.06.011
[4]	Zhihong LIU, Jianning JIANG, Minghua SU, Shihua LI, Bobin HU, Jiaxin FU, Yanping FU, Huijiao LI, Li GUO. Clinical effect of entecavir antiviral therapy in chronic hepatitis B patients with persistently normal alanine aminotransferase and mild liver histological abnormalities[J]. Journal of Clinical Hepatology, 2021, 37(8): 1789-1792. doi: 10.3969/j.issn.1001-5256.2021.08.009
[5]	Hou YiHui, Liu TengFei, Zhao XiaoQing, Zhang LiaoYun. Effect of different direct-acting antivirals on the clinical outcome of genotype 1b chronic hepatitis C and compensated hepatitis C cirrhosis[J]. Journal of Clinical Hepatology, 2020, 36(1): 84-87. doi: 10.3969/j.issn.1001-5256.2020.01.019
[6]	Liang Jing, Zhang YaPing, Liu Fang, Xiang HuiLing, Lu: HongMin, Han Tao. Efficacy of direct-acting antiviral agents in treatment of chronic hepatitis C and its effect on liver stiffness and aspartate aminotransferase-to-platelet ratio index[J]. Journal of Clinical Hepatology, 2020, 36(6): 1263-1267. doi: 10.3969/j.issn.1001-5256.2020.06.015
[7]	Chen QiJun, Shi Ling, Xiu ZiLi. Direct-acting antiviral agents for treatment of uremia with hepatitis C: A report of 2 cases[J]. Journal of Clinical Hepatology, 2019, 35(5): 1076-1078. doi: 10.3969/j.issn.1001-5256.2019.05.029
[8]	You GuoQiong, Wang Li, Duan Meng, Zhu Peng. Research advances in direct-acting antiviral agents in the treatment of hepatitis C virus-related liver cirrhosis[J]. Journal of Clinical Hepatology, 2019, 35(1): 187-190. doi: 10.3969/j.issn.1001-5256.2019.01.041
[9]	Zhang YaoDi, Zhang YueRong, Wang Hui, Lin Yan, Zhou Ning, Wu LiYang, Wei ShiFang, Li XiangLin. Clinical features of hepatitis C patients with failure or recurrence after treatment with pegylated interferon-α combined with ribavirin and the clinical effect of direct-acting antiviral agents[J]. Journal of Clinical Hepatology, 2019, 35(11): 2456-2460. doi: 10.3969/j.issn.1001-5256.2019.11.014
[10]	Ning HuiBin, Liu JunPing, Jin HuiMing, Li Kuan, Xiao ErHui, Shang Jia. Direct-acting antiviral durgs for hepatitis C in children: A case report[J]. Journal of Clinical Hepatology, 2019, 35(1): 164-165. doi: 10.3969/j.issn.1001-5256.2019.01.032
[11]	Chen JianHong, Xu XiaoYuan. Selection of direct-acting antiviral agents in treatment of chronic hepatitis C patients with renal dysfunction[J]. Journal of Clinical Hepatology, 2018, 34(2): 251-254. doi: 10.3969/j.issn.1001-5256.2018.02.007
[12]	An ZiYing, Ding Yang, Dou XiaoGuang. Selection and evaluation of treatment regimens with direct-acting antiviral agents for patients with chronic hepatitis C in the real world in China[J]. Journal of Clinical Hepatology, 2018, 34(2): 233-237. doi: 10.3969/j.issn.1001-5256.2018.02.003
[13]	Zhao XiTai, Nie QingHe. Adverse effects, drug interactions, and safety of direct-acting antiviral agents in treatment of hepatitis C[J]. Journal of Clinical Hepatology, 2017, 33(6): 1067-1074. doi: 10.3969/j.issn.1001-5256.2017.06.010
[14]	Ji WeiJia, Yan XueBing. A comparison of 2015 and 2016 EASL guidelines on treatment of hepatitis C: an analysis of direct-acting antiviral agents and drug-drug interaction[J]. Journal of Clinical Hepatology, 2017, 33(6): 1033-1039. doi: 10.3969/j.issn.1001-5256.2017.06.003
[15]	Bian DanDan, Zheng SuJun. Influencing factors for the therapeutic effect of direct-acting antiviral agents in hepatitis C[J]. Journal of Clinical Hepatology, 2017, 33(11): 2205-2208. doi: 10.3969/j.issn.1001-5256.2017.11.034
[16]	Chen XinYue, Liu YaLi, Ren Shan. Value of direct-acting antivirals combined with PR regimen (PEG-IFN combined with ribavirin) in the new era of antiviral therapy for hepatitis C[J]. Journal of Clinical Hepatology, 2017, 33(6): 1063-1066. doi: 10.3969/j.issn.1001-5256.2017.06.009
[17]	Ceng Qun, Jie ShengHua. Research advances in antiviral drugs and their treatment regimens in chronic hepatitis C[J]. Journal of Clinical Hepatology, 2017, 33(11): 2200-2204. doi: 10.3969/j.issn.1001-5256.2017.11.033
[18]	Wen XiaoYu, Niu JunQi. Mechanism of action of direct-acting antiviral agents in treatment of chronic hepatitis C[J]. Journal of Clinical Hepatology, 2016, 32(9): 1699-1705. doi: 10.3969/j.issn.1001-5256.2016.09.013
[19]	Liu HongLing, Zhang Min, Zang Hong, Zhou Xia, Yao Hong, Gao YinJie, Zhou ShuangNan, Liu ZhenWen. Clinical efficacy of direct-acting antiviral agents in treatment of patients with hepatitis C recurrence after liver transplantation[J]. Journal of Clinical Hepatology, 2015, 31(12): 2039-2041. doi: 10.3969/j.issn.1001-5256.2015.12.012
[20]	Zhang Jing, Liu XueMin, Liu ZhengWen, Lu: Yi. Application of direct-acting antiviral agents in perioperative period of liver transplantation for patients with hepatitis C[J]. Journal of Clinical Hepatology, 2015, 31(12): 2084-2087. doi: 10.3969/j.issn.1001-5256.2015.12.023

Supplements(0)

Cited By

Cited by
Periodical cited type(0)
Other cited types(2)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Tables(8)

Get Citation

PDF

XML

Article Metrics

Article views (568) PDF downloads(50)

Efficacy of antiviral therapy for chronic hepatitis B with nonalcoholic fatty liver disease

DOI: 10.3969/j.issn.1001-5256.2021.09.015

Abstract

References

Relative Articles

Cited by

Periodical cited type(0)

Other cited types(2)

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content